Drug Profile
Research programme: small molecule ophthalmic therapies - Alcon/Kalypsys
Latest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Kalypsys
- Developer Alcon; Kalypsys
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 26 Aug 2010 Alcon has been acquired by Novartis
- 06 Jan 2006 Preclinical trials in Eye disorders in USA (unspecified route)